Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cancer Immunol Immunother ; 71(5): 1157-1165, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-34618180

RESUMO

INTRODUCTION: Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data are available regarding either risk of irTCP or the effect of irTCP on clinical outcomes of patients treated with ICI. METHODS: We conducted a retrospective review of sequential cancer patients treated with ICI between 2011 and 2017 at our institution. All patients who received ICI alone or in combination with other systemic therapy in any line of treatment were included; those with thrombocytopenia ≥ grade 3 at baseline were excluded. We calculated the incidence of ≥ grade 3 irTCP and overall survival (OS). Patient factors associated with irTCP were assessed. RESULTS: We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade ≥ 3 thrombocytopenia; eighteen were attributed to ICI (1.73% overall). Patients who developed grade ≥ 3 irTCP had worse overall survival compared to those whose thrombocytopenia was unrelated to ICI (4.17 vs. 10.8 month; HR. 1.94, 95% CI 1.13, 3.33; log-rank p = 0.0164). Patients with grade ≥ 3 irTCP also had worse survival compared to those without thrombocytopenia (4.17 vs. 13.31 months; HR 2.22, 95% CI 1.36, 3.62; log-rank p = 0.001). The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy (p = 0.059) and was not associated with cancer type, smoking status, age, gender, race, or line of therapy. CONCLUSIONS: Unlike other irAEs, we found that irTCP was associated with worse overall survival. The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy.


Assuntos
Neoplasias , Trombocitopenia , Humanos , Inibidores de Checkpoint Imunológico/efeitos adversos , Incidência , Neoplasias/tratamento farmacológico , Receptor de Morte Celular Programada 1/uso terapêutico , Estudos Retrospectivos , Fatores de Risco , Trombocitopenia/induzido quimicamente , Trombocitopenia/tratamento farmacológico , Trombocitopenia/epidemiologia
2.
Am J Ophthalmol Case Rep ; 18: 100649, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32195441

RESUMO

PURPOSE: To describe the management of a symptomatic pterygium in an eye with previous LASIK surgery. OBSERVATIONS: Significant infiltration of the LASIK flap by the pterygium was noted intraoperatively necessitating the frequent use of a crescent blade. The infiltrative behavior of the pterygium may reflect the inflammatory state after laser refractive surgery. CONCLUSIONS AND IMPORTANCE: Pterygia are highly prevalent, and with the increasing prevalence of LASIK surgery, the coexistence of these 2 conditions is expected to be increasingly more likely. Optimizing the management of this condition can result in a good functional and cosmetic outcome.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA